Skip to main content
Median Technologies logo

Median Technologies — Investor Relations & Filings

Ticker · ALMDT ISIN · FR0011049824 LEI · 9695007YG6O07A8N6395 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 797 across all filing types
Latest filing 2025-02-11 Regulatory Filings
Country FR France
Listing PA ALMDT

About Median Technologies

https://mediantechnologies.com/

Median Technologies develops and provides innovative imaging solutions and services focused on oncology. The company utilizes proprietary artificial intelligence, computer vision, and signal processing technologies to transform medical images into actionable clinical insights. These insights aid healthcare professionals in the diagnosis, treatment, and monitoring of cancer. Median Technologies serves two primary markets: biopharmaceutical companies, by providing imaging services for oncology clinical trials, and healthcare providers, by offering software for clinical practice, including cancer screening. Its portfolio includes the eyonis® platform, designed for the early detection of cancer.

Recent filings

Filing Released Lang Actions
Modification des droits attachés aux catégories d'actions
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure titled 'Déclaration du nombre total de droits de vote et du nombre d'actions composant le capital', which is a standard monthly filing required by the AMF (Autorité des Marchés Financiers) in France. It provides the total number of shares and voting rights as of a specific date (January 31, 2025). This type of disclosure does not fit into specific categories like 'Major Shareholding Notification' (which concerns individual investors) or 'Share Issue' (which concerns changes in capital structure). Since it is a standard regulatory requirement for transparency regarding share capital and voting rights, it falls under the 'Regulatory Filings' category.
2025-02-11 French
Inside Information / Other news releases
Capital/Financing Update Classification · 100% confidence The document is a press release from Median Technologies detailing a financing agreement involving bonds redeemable in shares (equity line) and providing an update on the status of bond subscriptions and exercises. This falls under the category of company fundraising and financing activities, which is defined as Capital/Financing Update (CAP).
2025-02-05 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release from Median Technologies detailing a specific financing arrangement involving 'obligations remboursables en actions' (convertible bonds/equity-linked financing). It outlines the terms of the financing, the subscription by Iris Capital, and provides a table showing the status of the obligations and share issuance. This falls under the category of company fundraising and capital structure updates.
2025-02-05 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "Communiqué de presse" (Press Release) dated February 3, 2025. It announces key clinical trial results (RELIVE study for eyonis™ LCS) and subsequent regulatory filing timelines (FDA 510(k) and CE marking submissions planned for Q2 2025). This structure—announcing significant operational/clinical milestones and future regulatory actions via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on the immediate release of key performance/clinical data rather than a comprehensive periodic financial report (like 10-K or IR), and it is not a transcript (CT) or a formal proxy/governance document, it best fits the 'Earnings Release' category, which often encompasses major operational news releases. However, given the content is primarily clinical/regulatory progress rather than quarterly financial figures (though it mentions webcasts), and it is a general announcement, 'Regulatory Filings' (RNS) is a strong secondary candidate. Since the primary focus is the announcement of a major clinical success that *enables* regulatory submissions, and it is structured as a news announcement, ER is slightly more appropriate than RNS, which is often reserved for filings that don't fit elsewhere or routine updates. Given the context of financial reporting databases, major clinical breakthroughs announced via press release are often categorized alongside ERs or IP. I will select ER as it announces the 'results' that drive the next phase, similar to how ERs announce quarterly results.
2025-02-03 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is explicitly titled "Press Release - For immediate release" and announces key clinical trial results (RELIVE study met primary endpoint) for a medical device (eyonis™ LCS). It also details the next steps, which are regulatory filings (U.S. FDA 510(k) and EU CE marking) targeted for Q2 2025. This structure—announcing significant operational/clinical news via a press release, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a major, time-sensitive announcement of operational success that precedes formal financial reporting, it aligns best with the 'Earnings Release' category, which covers initial announcements of periodical results or major operational milestones. It is not a full 10-K, an Interim Report (IR), or a transcript (CT). Given the focus on a major operational/clinical milestone announcement, ER is the most appropriate fit over the general RNS. Q2 2025
2025-02-03 English
Inside Information / Other news releases
Earnings Release Classification · 100% confidence The document is a press release titled 'Median Technologies reports 2024 key financial indicators and 2025 outlook'. It provides unaudited preliminary financial highlights (revenue, order backlog, cash position) and strategic updates. It is not a full annual report (10-K/AR) but rather an initial announcement of financial results, which fits the definition of an Earnings Release (ER). FY 2024
2025-01-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.